Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2018

View Archived Issues

Tumor oxygen boost improves radiation response

CRISPR plus unusual cell line give insight into rare BRCA variants

Zika and testosterone don't mix

Virion Biotherapeutics builds team to guide focus on respiratory virus infection management

GamaMabs Pharma initiates phase II study of GM-102 in patients with colorectal cancer

Galectin-3 concentration in bronchial tissue and BAL correlates with asthma severity

Ilumetri receives approval in Europe for treatment of moderate to severe chronic plaque psoriasis

Ono collaborates with Fate Therapeutics on iPSC-derived CAR-T cell cancer therapies

Preclinical data presented for PIN-201104 as asthma therapy

Primary and key secondary endpoints met in pivotal phase III trial of dasiglucagon

CAM-2038 delivers durable pain relief in opioid-experienced patients in phase III trial

FDA approves Utility's INDs for mecillinam and pivmecillinam

Enrollment begins in phase Ib/IIa study of BioAegis' rhu-pGSN

Encouraging results seen in CHAMPIONS study of SB-913 in mucopolysaccharidosis type II

Phase I results with ContraVir's CRV-431 support further development for HBV

ARCA Biopharma submits SPA to FDA for phase III trial of Gencaro in atrial fibrillation

Investigators unveil BRWD1 gene mutation behind primary ciliary dyskinesia

NIDA award supports Ensysce's development of opioid overdose protection platform

Bavarian Nordic initiates phase II study of CV-301 with atezolizumab for bladder cancer

Sanofi achieves KEAP1/Nrf2 inhibition with bioavailable small molecules

Rapamycin Holdings initiates first-in-human study with eRapa in early-stage prostate cancer

UCB-9608 is a potent and orally available immunosuppressive agent with promising in vivo activity

First-in-human data presented for AZD-9496

Phase II results presented for BMS-986165 in patients with moderate to severe psoriasis

ICU patients without Enterobacteriaceae infection should not receive carbapenems

Design of potentially efficacious and safe small interfering RNAs against Zika virus infection

Identification of P. falciparum ER translocation interactome for protein export to the erythrocyte

Alector initiates phase I study of AL-001 for frontotemporal dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 10, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...